People · Operator
Named in public records as an officer, director or promoter · active 2009–2021 · Biotechnology, Other Health Care, Pharmaceuticals, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| TELA Bio, Inc. | — | Biotechnology | Series C | $104.8M | $435.1M | 2014 |
| NovaSom, Inc | — | Other Health Care | Series B | $53.9M | $82.0M | 2010 |
| Greenbrook TMS Inc. | — | Other Health Care | Series B | $50.6M | $187.1M | 2019 |
| Skinmedica Inc | — | Pharmaceuticals | Series B | $26.2M | $569.9M | 2009 |
| Semprae Laboratories Inc | — | Other | Series A | $8.2M | $62.0M | 2010 |
Adele C. Oliva at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Adele C. Oliva on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Adele Oliva | 3 | 9 |
| David F Hale | 1 | 16 |
| Christopher Smith | 1 | 15 |
| Kevin Rakin | 1 | 7 |
| Brian H. Dovey | 1 | 7 |
| Robert Higgins | 1 | 7 |
| Adrienne Graves | 1 | 6 |
| James A. Datin | 1 | 6 |
| William Leonard | 1 | 5 |
| D. Keith Grossman | 1 | 5 |
| Eran Nadav | 1 | 4 |
| Matt Zuga | 1 | 4 |
| Antony Koblish | 1 | 3 |
| Vince Burgess | 1 | 3 |
| Paul Touhey | 1 | 3 |
| Elias Vamvakas | 1 | 3 |
| Stan Blaylock | 1 | 3 |
| James H. Cavanaugh, Ph.D. | 1 | 3 |
| Rex Bright | 1 | 3 |
| Richard Kollender | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.